Brief: Atara Biotherapeutics Presents Positive Preclinical Data On ATA3431
11/12/2023 17:54
Dec 11 (Reuters) - Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS PRESENTS POSITIVE PRECLINICAL DATA
ON
ATA3431, A NEXT-GENERATION ALLOGENEIC CD20/CD19-TARGETED CAR, AT
THE 65TH ASH ANNUAL MEETING
* ATARA BIOTHERAPEUTICS INC - NO OBSERVED TREATMENT-RELATED
TOXICITIES OR ALLOREACTIVITY
* ATARA BIOTHERAPEUTICS INC - DATA SUPPORTS ADVANCEMENT INTO
IND-ENABLING STUDIES
* ATARA BIOTHERAPEUTICS INC - EXCITED THAT ATA3431 IS
PROGRESSING
TOWARDS AN IND SUBMISSION IN 2025
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing